Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,866 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Obesity
Interventions: Resistance training, Aerobic interval training; Other
Lead sponsor: Southern Illinois University Edwardsville; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Edwardsville, Illinois

Conditions: Bipolar Disorder
Interventions: Ziprasidone, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Orange City, Florida • Fayetteville, Georgia • Smyrna, Georgia + 6 more

Conditions: Melanoma
Interventions: Talimogene laherparepvec, GM-CSF; Biological
Lead sponsor: BioVex Limited; Industry
Eligibility: 18 Years and older
Enrollment: 437 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 57
States / cities: Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more

Conditions: Breast Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer
Interventions: Dietary Protein Intervention; Other
Lead sponsor: Josephine Connolly-Schoonen; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Perennial Allergic Rhinitis
Interventions: ciclesonide hydrofluoroalkane (HFA) nasal aerosol, mometasone nasal inhalation; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 6
States / cities: Mission Viejo, California • San Diego, California • North Dartmouth, Massachusetts + 3 more

Conditions: Advanced Colorectal Cancer
Interventions: MEDI4736; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Green tea, 70% dark chocolate; Dietary Supplement
Lead sponsor: LifeBridge Health; Other
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity
Interventions: overfeeding, growth hormone treatment; Other · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 35 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Lymphoma, AIDS-related, Lymphoma, Large B-Cell, Diffuse
Interventions: Rituximab, Filgrastim, EPOCH; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Heart Transplant
Interventions: tocilizumab, Placebo, Standard of Care Triple IS; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 20
States / cities: Beverly Hills, California • La Jolla, California • Stanford, California + 15 more

Conditions: Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
Interventions: Naloxone, Diazoxide, Placebo (for Naloxone), Placebo (for Diazoxide); Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 21 Years to 55 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Central Nervous System Infection
Interventions: Delve Detect CSF mNGS Test, Real-World Data; Diagnostic Test · Other
Lead sponsor: Delve Bio, Inc.; Industry
Eligibility: Not listed
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 3 more

Conditions: Venous Thrombosis
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin followed by VKA; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 3,449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 23
States / cities: Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more

Conditions: Myelodysplastic Syndromes
Interventions: Dasatinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chronic Pain
Interventions: Interpersonal Social Rhythms Psychotherapy, Bright Light Device; Behavioral · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Advanced Liver Cancer
Interventions: ABSK-011; Drug
Lead sponsor: Abbisko Therapeutics Co, Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 6
States / cities: Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 3 more

Conditions: Cognitive Function, Depression in Old Age
Interventions: Physical exercise (PE) training and computer-based brain (CBB); Behavioral
Lead sponsor: Yale University; Other
Eligibility: 65 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Kidney Cancer, Renal Cell Carcinoma
Interventions: Cabozantinib, Nivolumab, Cytoreductive nephrectomy; Drug · Procedure
Lead sponsor: Mark Stein; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 4
States / cities: New Brunswick, New Jersey • New York, New York • Cleveland, Ohio + 1 more

Conditions: Major Depressive Disorder
Interventions: Clopidogrel, LY2216684; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Usual Care, Intervention Arm; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 10
States / cities: Lewes, Delaware • Savannah, Georgia • Chicago, Illinois + 7 more

Conditions: Lung Diseases, Interstitial
Interventions: Nintedanib, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 9
States / cities: Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 6 more

Conditions: Embryo Transfer
Interventions: Epelsiban, Placebo, Oxytocin, Ortho-Cylcen (21)® tablet; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: SAR445088 (IV), SAR445088 (SC); Drug
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Fairway, Kansas + 2 more

Conditions: Autoimmune Inner Ear Disease, Meniere's Disease
Interventions: Anakinra 100Mg/0.67Ml Inj Syringe (Period 1), Placebo injection (Period 1), Anakinra 100Mg/0.67Ml Inj Syringe (Period 2), Placebo injection (Period 2); Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: New Hyde Park, New York

Search by objective public record fields.

Effects of Exercise Mode on Cardiac Fat and Function

Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Short-Term Reduced Dietary Protein in ER+/HER2- Breast Cancer Patients During Neoadjuvant Chemotherapy

Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis

Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer

Flavonoid Effect on Activation and Stimulation of Thrombocytes, hsCRP and Lipid Profile

Growth Hormone as a Determinant of Weight Regulation

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

Tocilizumab in Cardiac Transplantation

Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)

Investigation of the Delve Detect Cerebrospinal Fluid (CSF) Metagenomic Next-generation Sequencing (mNGS) Test When Used for the Initial Diagnostic Workup of Patients With Suspected Central Nervous System (CNS) Infection

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

Social & Behavioral Rhythms in Chronic Pain

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

Computer Presented and Physical Exercises to Maintain Cognitive Function and Emotional Health in Older Adults

CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition

A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel

Improving Resection Rates Among African Americans With NSCLC

A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)

A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban

Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease